Original contribution
Enhanced resistance to oxidation of low density lipoproteins and decreased lipid peroxide formation during β-carotene supplementation in cystic fibrosis

https://doi.org/10.1016/0891-5849(94)00203-VGet rights and content

Abstract

We investigated the effect of correcting β-carotene deficiency in cystic fibrosis (CF) patients on two parameters of lipid peroxidation: The resistance to oxidation of low density lipoprotein (LDL) was measured by the lag time preceding the onset of conjugated diene formation during exposure to copper(II) ions, and lipid peroxide formation was quantitated by malondialdehyde concentrations in plasma (TBA/HPLC method). Simultaneously, α-tocopherol and β-carotene concentrations were determined in LDL and in plasma. Thirty-four CF patients were investigated before and after 3 months of oral β-carotene supplementation. β-carotene concentrations increased (p < 0.0001) in plasma (mean ± SD) (0.09 ± 0.06 vs. 1.07 ± 0.86 μmol/1) and in LDL (0.02 ± 0.02 vs. 0.31 ± 0.28 mol/mol), without significant changes in α-tocopherol, either in plasma (24.7 ± 5.9 vs. 25.4 ± 7.6) or in LDL (8.47 ± 2.95 vs. 9.05 ± 4.13). Lag times, being shorter (p < 0.05) in patients than in controls, increased from 48.5 ± 21.3 to 69.1 ± 27.9 min (p < 0.001) and plasma MDA concentrations, being greater (p < 0.0001) in patients than in controls, decreased from 0.95 ± 0.32 to 0.61 ± 0.15 μmol/l (p < 0.0001). At 3 months, lag times and MDA concentrations did not any longer differ between patients and controls. These data suggest that excess lipid peroxidation occurring in β-carotene deficiency can be limited and normalized during efficient β-carotene supplementation in CF patients.

References (44)

  • P. Palozza et al.

    The inhibition of radical-initiated peroxidation of microsomal lipids by both α-tocopherol and β-carotene

    Free Radic. Biol. Med.

    (1991)
  • P. Palozza et al.

    β-carotene and α-tocopherol are synergistic antioxidants

    Arch. Biochem. Biophys.

    (1992)
  • D.W. Morel et al.

    Low density lipoprotein cytotoxicity induced by free radical peroxidation of lipid

    J. Lipid Res.

    (1983)
  • V.W.M. Van Hinsbergh et al.

    Role of endothelial cells and their products in the modification of low density lipoproteins

    Biochim. Biophys. Acta

    (1986)
  • I. Jialal et al.

    β-carotene inhibits the oxidative modification of low-density lipoprotein

    Biochim. Biophys. Acta

    (1991)
  • M. Abbey et al.

    Oxidation of low-density lipoproteins: Intraindividual variability and the effect of dietary linoleate supplementation

    Am. J. Clin. Nutr.

    (1993)
  • G. Lepage et al.

    Direct transesterification of plasma fatty acids for the diagnosis of essential fatty acid deficiency in cystic fibrosis

    J. Lipid Res.

    (1989)
  • H.M.G. Princen et al.

    Supplementation with vitamin E but not β-carotene in vivo protects low density lipoprotein from lipid peroxidation in vitro: Effect of cigarette smoking

    Arterioscler. Thromb.

    (1992)
  • P.D. Reaven et al.

    Effect of dietary antioxidant combinations in humans: Protection of LDL by vitamin E but not by β-carotene

    Arterioscler. Thromb.

    (1993)
  • I. Jialal et al.

    Effect of combined supplementation with α-tocopherol, ascorbate, and beta carotene on low-density lipoprotein oxidation

    Circulation

    (1993)
  • C.M.F. Kneepkens et al.

    Low beta-carotene may contribute to the accumulation of free radicals in cystic fibrosis (CF)

    Pediatr. Res.

    (1991)
  • G. Lepage et al.

    Beta-carotene inhibits lipid peroxidation and improves peroxisomal function in cystic fibrosis (CF)

    FASEB J.

    (1993)
  • Cited by (96)

    • Circulating biomarkers of antioxidant status and oxidative stress in people with cystic fibrosis: A systematic review and meta-analysis

      2020, Redox Biology
      Citation Excerpt :

      Eleven studies were eligible and studied the levels of lipid peroxidation within the plasma or serum of people with CF versus non-CF controls. The biomarkers studied were MDA (inclusive of the thiobarbitoric acid reactive substances [TBARS] assay) (n = 7) [7,42,54,56,58,61,64,72,74], hydroperoxides (n = 3) [43,64,72] and total 8-iso-PGF2α (n = 3) [41,58,75]. The concentration of MDA (SMD 1.33, 95% CI 0.43 to 2.24, p < 0.01, I2 96%, 8 trials; Fig. 3) [7,54,56,58,61,64,72,74] and total 8-iso-PGF2α (SMD 0.64, 95% CI 0.23 to 1.05, p < 0.01, I2 0%, 2 trials; Fig. 3) [58,75] in the plasma or serum were significantly higher in people with clinically-stable CF compared to the non-CF controls (Fig. 3).

    • Inflammation, oxidative stress, and cardiovascular disease risk factors in adults with cystic fibrosis

      2014, Free Radical Biology and Medicine
      Citation Excerpt :

      Numerous other clinical conditions remain uncertain as to their potential contribution to atherosclerotic CVD risk factors in patients with CF, partly due to their controversy within the general population. These clinical conditions include issues related to reduced coenzyme Q10 levels in patients with CF [306] and often reduced levels of carotenoids, vitamin E, and vitamin D, all of which have even been touted as factors influencing the incidence and/or severity of atherosclerotic CVD [159,307–310]. Such factors as the “anti-inflammatory” agents NSAIDS, glucosteroids, and azithromycin have been touted as presenting an increased risk of CVD in the general population [297,311] but are frequently prescribed to patients with CF. Finally, elevated homocysteine levels have been found in children with CF [312] and could represent another factor influencing CVD incidence [313].

    • Oxidative stress and antioxidant therapy in cystic fibrosis

      2012, Biochimica et Biophysica Acta - Molecular Basis of Disease
      Citation Excerpt :

      The tolerable upper intake level (UL) and the Acceptable Daily Intake (ADI), established by the Joint FAO/WHO Expert Committee on Food Additives for the natural form of vitamin E as α-tocopherol equivalents are of 300 mg/die and 0.15–2.0 mg/kg body weight/die, respectively [172,177]. Levels of plasma carotenoids such as β-carotene, β-cryptoxanthin, and total lycopene are significantly lowered in CF patients and this was associated with higher susceptibility to lipid peroxidation [5,178–180]. Rust et al. [178] demonstrated that the long-term oral supplementation with 50 mg β-carotene/day (i.e. 1 mg β-carotene/kg BW/day) restored the levels of this carotenoid, while sub-optimal supplementation was observed at doses of 10 mg β-carotene/day or lower, thus confirming the need of high doses of this fat-soluble factor to overcome the limited absorption and thus to achieve plasma concentrations of healthy control subjects.

    View all citing articles on Scopus
    View full text